Tysabri

Roche sues Biogen over royalties related to multiple sclerosis drug Tysabri
Roche sues Biogen over royalties related to multiple sclerosis drug Tysabri
Fierce Pharma
Roche
Genentech
patents
MS
multiple sclerosis
legal
Tysabri
Flag link:
Unsealed documents detail Biogen's fight against Sandoz Tysabri biosimilar
Unsealed documents detail Biogen's fight against Sandoz Tysabri biosimilar
Endpoints
Biogen
Novartis
Sandoz
biosimilars
Tysabri
MS
multiple sclerosis
Flag link:
Biogen, watch out: Novartis' Tysabri biosim application could portend multiple sclerosis showdown in Europe and US
Biogen, watch out: Novartis' Tysabri biosim application could portend multiple sclerosis showdown in Europe and US
Fierce Pharma
Novartis
Biogen
multiple sclerosis
MS
Tysabri
biosimilars
Flag link:
Novartis asks FDA to approve biosimilar for Biogen’s top-selling MS drug
Novartis asks FDA to approve biosimilar for Biogen’s top-selling MS drug
BioPharma Dive
Novartis
FDA
Biogen
biosimilars
Tysabri
MS
multiple sclerosis
Flag link:
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
Xtalks
stem cells
MS
multiple sclerosis
NIH
AHSCT
Biogen
Tysabri
Sanofi
Lemtrada
Roche
Ocrevus
Rituxan
Flag link:
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar
Pharmaforum
Novartis
Sandoz
generics
biosimilars
Tysabri
Polpharma
Flag link:
Biogen scuttles a Tysabri program after the drug fails stroke test, thinning the pipeline
Biogen scuttles a Tysabri program after the drug fails stroke test, thinning the pipeline
Endpoints
Biogen
Tysabri
ischemic stroke
Flag link:
How Biogen Inc. Makes Most of Its Money
How Biogen Inc. Makes Most of Its Money
Motley Fool
Biogen
Tecfidera
Tysabri
MS
multiple sclerosis
Flag link:
Why Roche's New Drug Is Bad News For Biogen
Why Roche's New Drug Is Bad News For Biogen
Barron's
Roche
Biogen
Ocrevus
multiple sclerosis
MS
Tysabri
Tecfidera
Flag link:
Biogen Inc MS Drugs: Deadly Cash Cows?
Biogen Inc MS Drugs: Deadly Cash Cows?
Bidness, ETC
Biogen
MS
multiple sclerosis
Tecfidera
Avonex
Tysabri
Plegridy
Flag link:
Perrigo Can Reach $200 If It Keeps Tysabri Royalties, Lot More If It Sells Them
Perrigo Can Reach $200 If It Keeps Tysabri Royalties, Lot More If It Sells Them
Seeking Alpha
Perrigo
Tysabri
Flag link:
Biogen shares could rise 20% on robust drug pipeline, Barron's contends
Biogen shares could rise 20% on robust drug pipeline, Barron's contends
The Fly on the Wall
Biogen Idec
Tysabri
Avonex
Tecfidera
Eloctate
Alprolix
Flag link:
Catalyst For Perrigo: Sale Of Tysabri Royalties
Catalyst For Perrigo: Sale Of Tysabri Royalties
Seeking Alpha
Perrigo
Tysabri
Biogen Idec
Flag link:
Elan sees sales of prized Tysabri drug rise sharply
Elan sees sales of prized Tysabri drug rise sharply
Reuters
Elan
Royalty Pharma
M&A
Tysabri
Flag link:
Elan completes sale of Tysabri stake to Biogen
Elan completes sale of Tysabri stake to Biogen
Reuters
Tysabri
Elan
Biogen Idec
MS
multiple sclerosis
Flag link:
Elan offers Tysabri dividend, dismisses Royalty offer
Elan offers Tysabri dividend, dismisses Royalty offer
Reuters
Elan
dividends
Tysabri
Royalty Pharma
Flag link:
Elan to return $1 billion to shareholders from multiple sclerosis drug sale
Elan to return $1 billion to shareholders from multiple sclerosis drug sale
Reuters
Elan
Tysabri
share repurchase
Flag link:
A Strong Growth Opportunity In Multiple Sclerosis
A Strong Growth Opportunity In Multiple Sclerosis
Motley Fool
multiple sclerosis
MS
Elan
Biogen Idec
Tysabri
Teva
XenoPort
Sanofi
BG-12
Flag link:
Elan seeks acquisitions after $3.25 bn Biogen Idec deal, rival Bayer eyed on MS treatments
Elan seeks acquisitions after $3.25 bn Biogen Idec deal, rival Bayer eyed on MS treatments
Financial Express
Elan
Bayer
M&A
Biogen Idec
Tysabri
Flag link:
A Win-Win Multiple Sclerosis Deal?
A Win-Win Multiple Sclerosis Deal?
Motley Fool
MS
multiple sclerosis
Tysabri
Biogen Idec
Elan
Flag link:

Pages